Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology

European Journal of Immunology

Volumn 31, Issue 9, 2001, Pages 2566-2573

  Hussell, Tracy ^a   Pennycook, Alasdair ^a   Openshaw, Peter J M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bronchiolitis; Immunopathology; Lung disease; Respiratory syncytial virus; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; XT 22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLEARANCE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HYPOTHESIS; IMMUNOPATHOLOGY; INFLAMMATORY CELL; INFLUENZA VIRUS; LUNG DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODIES, VIRAL; BRONCHIOLITIS, VIRAL; CYTOKINES; FEMALE; LUNG; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PULMONARY EOSINOPHILIA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 0034807183     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L     Document Type: Article

References (43)

1. Immunopathological mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus
2. Vaccines and cytokine-mediated pathology in RSV infection
3. Respiratory syncytial virus infection
4. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
5. Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and effective immunization
6. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab
7. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
8. Advances in antiviral therapy
9. Recent developments in the biology of respiratory syncytial virus - Are vaccines and new treatments just round the corner?
10. Tumor necrosis factor: A master-regulator of leukocyte movement
11. On the role of tumor necrosis factor and receptors in models of multi-organ failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
12. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis
13. Antibodies to tumor necrosis factor α as treatment for Crohn's disease
14. Etanercept in children with polyarticular juvenile rheumatoid arthritis
15. Distinct types of lung disease caused by functional subsets of antiviral T cells
16. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection
17. Virus specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus Infection
18. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins
19. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages
20. Respiratory syncytial virus replication in human lung epithelial cells: Inhibition by tumor necrosis factor α and interferon β
21. Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo
22. Challenging cytokine redundancy: Inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice
23. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation
24. Chemokine networks in vivo: Involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha
25. Contribution of tumor necrosis factor alpha and interleukin-1 alpha on the production of macrophage inflammatory protein-2 in response to respiratory syncytial virus infection in a murine macrophage cell line, RAW264. 7
26. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus
27. IL-12 induces Th1 responses but does not prevent vaccine-enhanced illness during viral challenge
28. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells
29. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis
30. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations
31. Tumor necrosis factor and immunopathology
32. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense
33. TNF alpha, interferon, and stress response induction as a function of age-related susceptibility to fatal Sindbis virus infection of mice
34. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system
35. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment
36. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor
37. Respiratory syncytial virus G-protein modulates cytokine release from human peripheral blood mononuclear cells
38. Polymorphism of the 5′-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T cell lymphotropic virus type I (HTLV-I) uveitis
39. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
40. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population
41. Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of, disease?
42. Respiratory syncytial and parainfluenza viruses
43. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus